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Phosphorylation and Inactivation of BAD
by Mitochondria-Anchored Protein Kinase A
tissuesandthemaintenanceofnormaltissuehomeosta-
sis. In order for cells to avoid a suicidal fate, they must
receive cues from their extracellular environment (Raff,
Hisashi Harada,*† Brian Becknell,*
Matthias Wilm,§ Matthias Mann,§
Lily Jun-shen Huang,k Susan S. Taylor,k
John D. Scott,‡ and Stanley J. Korsmeyer*†# 1992). A series of cytokines, such as interleukin-3 (IL-3),
nerve growth factor (NGF), or insulin-like growth factor *Division of Molecular Oncology
Howard Hughes Medical Institute (IGF), function as survival factors and transduce signals
throughsurfacereceptorstoincreasecellularresistance Washington University School of Medicine
St. Louis, Missouri 63110 to apoptosis. Downstream of these proximal signals lie
the BCL-2 family of proteins, which themselves reside †Departments of Pathology and Medicine
Harvard Medical School upstream to the irreversible damage of cellular constit-
uents. The pro- versus antiapoptotic BCL-2 members Dana-Farber Cancer Institute
One Jimmy Fund Way constitute a critical, decisional checkpoint that helps
determine how cells respond to proximal death and sur- Boston, Massachusetts 02115
‡Howard Hughes Medical Institute vival signals (Oltvai et al., 1993). Activation of proapo-
ptoticBCL-2memberssuchasBAXresultsintheactiva- Vollum Institute
Oregon Health Sciences University tion of caspases as well as the onset of mitochondrial
dysfunction (Xiang et al., 1996; Pastorino et al., 1998). Portland, Oregon 97201
§EMBL Consequently, BCL-2 members represent an attractive
target for posttranslational modification in response to Protein and Peptide Group
Heidelberg proximal signaltransduction events inorder toalter sus-
ceptibility to apoptosis. Germany
kHoward Hughes Medical Institute BAD represents a divergent BCL-2 family member
belonging to a subset that shares substantial sequence Department of Chemistry and Biochemistry
School of Medicine homology only within the BH3 amphipathic a-helical
domain (Yang et al., 1995; Zha et al., 1997). Members of University of California
La Jolla, California 92093 this “BH3 domain–only” subset include the mammalian
BID, BIK, BIM, BLK, and HRK molecules, all of which
are proapoptotic, lending support to the thesis that BH3
represents a minimal death domain (Boyd et al., 1995; Summary
Wang et al., 1996b; Inohara et al., 1997; Hegde et al.,
1998;O’Connoretal., 1998).Moreover,theidentification Signaling pathways between cell surface receptors
of a BH3 domain–only member in Caenorhabditis ele- and the BCL-2 family of proteins regulate cell death.
gans, EGL-1, which maps upstream to CED-9 and regu- Survivalfactorsinducethephosphorylationandinacti-
lates all developmental deaths, argues that these mole- vation of BAD, a proapoptotic member. Purification
cules are conserved components of the central death of BAD kinase(s) identified membrane-based cAMP-
pathway (Conradt and Horvitz, 1998). Deletion mapping dependent protein kinase (PKA) as a BAD Ser-112
and site-directed mutagenesis indicated that the BH3 (S112) site-specific kinase. PKA-specific inhibitors
domain of BAD was critical for its heterodimerization blocked the IL-3-induced phosphorylation on S112 of
withBCL-XLorBCL-2aswellasitsdeathagonistactivity endogenous BAD as well as mitochondria-based BAD
(Kelekar et al., 1997; Ottilie et al., 1997; Zha et al., 1997). S112 kinase activity. A blocking peptide that disrupts
ThisisconsistentwiththeNMRanalysisofaBH3amphi- type II PKA holoenzyme association with A-kinase-
pathic a-helical peptide from BAK within the BCL-XL anchoring proteins (AKAPs) also inhibited BAD phos-
pocket (Sattler et al., 1997). BAD lacks the typical hy- phorylation and eliminated the BAD S112 kinase activ-
drophobic COOH-terminal sequence that in the case of ity at mitochondria. Thus, the anchoring of PKA to
BCL-2 is required for its targeting mitochondria (Nguyen mitochondriarepresentsafocusedsubcellularkinase/
etal.,1993).Consistentwiththis,BADdisplayscytosolic substrate interaction that inactivates BAD at its target
as well as membrane-associated localizations and may organelle in response to a survival factor.
represent a death ligand (Wang et al., 1996b) that trans-
locates between cytosol and membrane-based BCL-2
or BCL-XL. Introduction
In the presence of a requisite survival factor, IL-3,
cells phosphorylated BAD on two serine residues (S112 Programmed cell death is a distinct genetic pathway
and S136) embedded within 14-3-3 consensus binding with evolving biochemical detail. This apoptotic path-
sites (Zha et al., 1996). This has the dual impact of dic- way, apparently shared by all multicellular organisms,
tating BAD’s location as well as its protein partners. is critical for the successful development of multiple
Phosphorylated BAD appears to be the inactive moiety
sequestered in the cytosol bound to 14-3-3, freeing
BCL-XL or BCL-2 to promote survival. Only the active, #To whom correspondence should be addressed (e-mail: stanley
_korsmeyer@dfci.harvard.edu). nonphosphorylated BAD heterodimerized with BCL-XLMolecular Cell
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Figure 1. Localization of BAD Kinase(s)
IL-3 was withdrawn from FL5.12 BCL-XL/BAD cells for 2 hr (2IL-3),
followed by readdition of IL-3 for 15 min (1IL-3). Cells were fraction-
ated into cytosol, heavy membrane, and light membrane fractions.
An in vitro kinase assay was performed with GST, GST-BAD wild-
type (GST-BAD), and GST-BAD whose S112 and S136 were substi-
tuted to alanine (GST-BAD112A136A) as substrates. The arrow indi-
cates the position of phosphorylated GST-BAD.
or BCL-2 at membrane sites to promote cell death.
Moreover, BAD that was singly phosphorylated on S112
proved incapable of binding BCL-XL, implying a confor-
mational change that masks the BH3 domain (Zha et
Figure 2. AKT Does Not Appear to Be the Principal BAD Kinase(s) al., 1996). Functionally, the rapid phosphorylation of
(A) IL-3 was withdrawn from FL5.12 BCL-XL/BAD cells for 2 hr BAD that follows IL-3 connects proximal survival signal-
(2IL-3), followed by readdition of IL-3 for 15 min (1IL-3). Whole-cell
ing with the BCL-2 family, resetting this checkpoint for extracts were then immunoprecipitated with an anti-AKT antibody
apoptosis. Thus, identifying the signaling components (a-AKT). An AKT kinase assay was performed with the immunopre-
between the surface receptor and BAD, including the cipitates (IP), and histone H2B, GST-BAD, and GST-BAD112A136A
as substrates (lanes 1–3, and 5–7). The BAD kinase assay was also identification of the BAD kinase(s), is a critical objective
performed using the supernatant following successful depletion of in the interconnection of signal transduction and distal
AKT by an anti-AKT antibody (IP-sup), with GST-BAD as a substrate death effector pathways. Recently, AKT/PKB/RAC, a
(lanes 4 and 8). A Western blot of the a-AKT immunoprecipitate
Ser/Thr kinase downstream of phosphatidylinositol (IP) and the supernatant (IP-sup) was developed with anti-AKT Ab,
3-kinase (PI-3K), was shown to be capable of phosphor- confirming the effectiveness of the immunodepletion.
ylating S136 of BAD. Moreover, expression of AKT will (B) Whole-cell extracts from IL-3-stimulated cells as in (A) were
assayed for BAD kinase activity before and after immunodepletion block the death of cells induced by expression of BAD
of AKT (a-AKT IP-sup). (Datta et al., 1997; del Peso et al., 1997; Blume-Jensen
et al., 1998). In addition, BAD is also inactivated in vivo
by phosphorylation on S112, prompting our purification
that contain a conserved anchoring domain that associ- of that responsible kinase.
ates with RII and unique targeting sequences that direct The differential phosphorylation of highly selected
the PKA holoenzyme complex to specific subcellular protein substrates is a key element in the surprising
addresses including the mitochondria (Carr et al., 1992; specificity that follows engagement of surface recep-
Lin et al., 1995; Huang et al., 1997). Here we purify an tors. Signaling cascades downstream of receptors often
IL-3-inducedkinaseresponsibleforthephosphorylation employ rather ubiquitous intermediates, raising impor-
of S112 of BAD. It proves to be mitochondria-tethered tant questions as to how activated kinases and phos-
PKA, thus focusing the inactivation of BAD to the site phatasespreferentiallyphosphorylatetargetsubstrates.
where it damages an organelle. An attractive “targeting hypothesis” holds that phos-
phorylation is controlled at least in part by localization
of individual kinases and phosphatases to distinct sub- Results
cellular compartments (Hubbard and Cohen, 1993;
Mochly-Rosen, 1995; Pawson and Scott, 1997). A strik- Localization of BAD Kinase Activity
TodeterminewhetheraBAD-specifickinaseisactivated ing example of subcellular targeting of kinase activity
isthe typeIIcAMP-dependentkinase (PKA)holoenzyme in response to the survival factor IL-3, we established
an in vitro kinase assay. To insure specificity, GST-BAD (Dell’AcquaandScott,1997).ThePKAholoenzymecom-
plex is comprised of an inhibitory regulatory R subunit wild-type and a GST-BAD mutant protein whose S112
and S136 residues were substituted to Ala were com- dimer that holds two catalytic C subunits in a dormant
state. Another property of the RII dimer is its direction pared as substrates. We utilized an IL-3-dependent cell
line, FL5.12, to examine BAD kinase(s) in that the differ- of the subcellular location of PKA holoenzyme through
its association with a series of tethering proteins known ential phosphorylation of BAD following IL-3 addition
or withdrawal dictates cell survival (Zha et al., 1996). as A-kinase-anchoring proteins (AKAPs). AKAPs repre-
sent a functionally related family of signaling proteins Subcellular fractions of FL5.12 cells expressing BCL-XLPhosphorylation of BAD by Mitochondria-Anchored PKA
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Figure 3. Purification of the BAD Ser-112-Specific Kinase
(A) The purification scheme used for a BAD S112–specific kinase.
(B) The phenyl-Sepharose fraction (column 3 in [A]) that shows a BAD kinase activity was chromatographed on a Mono Q column, and the
bound proteins were eluted with a NaCl gradient (the region of the gradient from 80 mM to 380 mM NaCl is shown). Fractions 5–16 were
assayed for BAD kinase activity with GST-BAD wild-type as a substrate.
(C) Left, a silver-stained gel of fraction 5 from the Mono Q column. Right, a Western blot of the same fraction using an anti-PKA catalytic
subunit antibody.
(D) Purified BAD kinase (Mono Q, fraction 5) was tested for its ability to phosphorylate GST-BAD wild-type (BAD wt), and GST-BAD whose
S112 and/or S136 were substituted to Ala (112A, 136A, and 112A136A). Purified PKA catalytic subunit (Sigma) was used to show Ser-112
specificity of BAD phosphorylation in vitro.
(E) An alternative purification scheme used for a BAD S112–specific kinase.
(F) A Western blot of the peak fraction of BAD kinase activity (fraction 7) from a Mono S column using an anti-PKA regulatory subunit type II
(left) and an anti-PKA catalytic subunit (right) antibody.
and BAD (FL5.12 BCL-XL/BAD) following the deprivation shown to be capable of phosphorylating the S136 site of
BAD and, when overexpressed, blocked BAD-induced of IL-3 (2 hr) or its readdition (15 min) were examined.
Only low-level BAD kinase activity was detected in the death of primary neurons (Datta et al., 1997). Overex-
pression of AKT has also been reported to inhibit IL-3 absence of IL-3. Exposure to IL-3 markedly induced
kinase activity for wild-type BAD but not the BAD deprivation death (del Peso et al., 1997; Songyang et
al., 1997). However, to assess whether AKT was the 112A136A mutant. Moreover, this IL-3-activated kinase
was predominantly localized to the heavy membrane endogenous kinase primarily responsible for the phos-
phorylation of BAD followingIL-3 treatment, we pursued (enriched for mitochondria) and light membrane (en-
riched for endoplasmic reticulum) fractions (Figure 1). an immunodepletion approach. AKT was immunopre-
cipitated by an anti-AKT antibody (Franke et al., 1995) Therefore, a crude membrane fraction of FL5.12 BCL-
XL/BAD cells cultured in the presence of IL-3 was used that recognizes AKT1 and AKT2, and in vitro kinase
assays were performed. AKT phosphorylated its classic as the source to purify the BAD kinase(s) (see Figures
3A and 3E). substrate H2B robustly (Figure 2A, lanes 3 and 7). Com-
paratively, BAD was only minimally phosphorylated by
the immunoprecipitated AKT (Figure 2A, lanes 1 and 5). AKT Does Not Appear to Be the Principal BAD
Kinase following IL-3 Stimulation However, BAD kinase activity increased approximately
10-fold following IL-3 but resided principally in the AKT- AKT (protein kinase B/RAC) is a Ser/Thr kinase down-
stream of PI-3 kinase and has been shown to suppress depleted extract (Figure 2A, lanes 4 and 8; Figure 2B).
These results argue that AKT is not the major kinase apoptosis following a variety of stimuli in multiple cell
types (Franke et al., 1997). The pS112 and pS136 14-3-3 responsible for the site-specific phosphorylation of BAD
following IL-3 receptor engagement. binding sites of BAD constitute attractive consensus
sites for AKT phosphorylation. Recently, AKT has been Raf-1, a Ser/Thr kinase in the MAPK pathway, canMolecular Cell
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weakly phosphorylate BAD (Wang et al., 1996a; Zha et
al., 1996). However, immunoprecipitates of Raf-1 in an
in vitro kinase assay revealed that the mutant GST-BAD
112A136A was phosphorylated just as well as wild-type
BAD (data not shown). This result, together with the
results using kinase inhibitors (see Figure 5), indicates
that Raf-1 is not the principal kinase.
Purification of Protein Kinase A as a
Ser-112-Specific BAD Kinase
A series of column chromatography purification steps
were utilized to enrich the kinase activity from the mem-
brane fraction of IL-3-stimulated cells that had specific-
ityforwtBADbutnotmutantBAD112A136A(Figure3A).
The peak BAD kinase activity was present in fractions 5
and 6 from the final, Mono Q column (Figure 3B). A
silver-stained SDS-PAGE gel of fraction 5 revealed a
prominent 40 kDa band (Figure 3C). Nano-electrospray
mass spectroscopy identified the protein as the a cata-
lytic subunit of protein kinase A. Furthermore, Western
blot analysis of fraction 5 confirmed that the 40 kDa
protein was PKAc (Figure 3C). Furthermore, the purified
Figure 4. Ser-112-SpecificBADKinaseInducedbyIL-3intheHeavy BAD kinase of fraction 5 displayed S112 specificity typi-
Membrane Fraction Is Blocked by a PKA-Specific Inhibitor cal of PKAc (Figure 3D). These results implicate PKAc
(A) S112 and S136 BAD kinase activities in the heavy membrane as the candidate kinase for S112 phosphorylation in
fraction are induced by IL-3. IL-3 was withdrawn from FL5.12 BCL- vivo. Of note, S136-specific BAD kinase activity was
XL/BAD cells for 2 hr (2IL-3), followed by readdition of IL-3 for 15
noted to separate from S112 kinase activity during the min (1IL-3). The heavy membrane fractions were used for an in vitro
chromatographic purification steps (data not shown). kinase assaywith BADwt, 112A, 136A,and 112A136Aas substrates.
An alternative column chromatography purification (B) PKA-specific inhibitor peptide, PKI, blocks S112-specific BAD
kinase activity induced by IL-3. The heavy membrane fraction of scheme revealed a peak of S112-specific kinase activity
FL5.12 BCL-XL/BAD cells induced by IL-3 was used for an in vitro in fraction 7 from the final, Mono S column (Figure 3E).
kinase assay with (100 nM) or without PKI. Lower numbers indicate Of note, immunoblot analysis revealed the presence of
the relative phosphorylation level of each substrate when the level
the 54 kDa PKA regulatory subunit type II (PKARII) dou- of GST-BAD wild-type phosphorylation without PKI is considered
blet copurifying with PKAc in this fraction (Figure 3F). It as 100% measured by phosphorimage analyzer. Data shown are
has been established that the type II PKA holoenzyme representative of four independent experiments.
(C) A PKA inhibitor, H-89, inhibits the IL-3-induced S112 kinase is targeted to select intracellular sites by association of
activity. The heavy membrane fractions of the IL-3-induced FL5.12 the regulatory RII subunit with a series of A-kinase-
BCL-XL/BAD cells treated with (10 mM) or without H-89 were used anchoring proteins (AKAPs) (Dell’Acqua and Scott,
for an in vitro kinase assay. Lower numbers indicate the relative
1997). Thus, the above results suggested a thesis for phosphorylation level of each substrate when the level of GST-
further testing: that PKA tethered to membranes by RII/ BAD wild-type phosphorylation without H-89 is considered as 100%
AKAP interaction could provide a localized pool of an- measured by phosphorimage analyzer. Data shown are representa-
tive of three independent experiments. chored PKA responsible for the phosphorylation on
S112 of BAD.
PKA Inhibitors Block IL-3-Induced Phosphorylation
of Endogenous BAD
Mitochondrial Membrane-Based S112 BAD Kinase To examine the phosphorylation of BAD in vivo, FL5.12
Is Activated by IL-3 and Blocked by PKA Inhibitors BCL-XL/BADcellswerelabeledwith 32P-orthophosphate
We next examined site-specific BAD kinase activity in andimmunoprecipitatedwithananti-BADantibody(Zha
the mitochondrial heavy membrane fraction from cells et al., 1996). There was very little residual phosphoryla-
maintained in or deprived of IL-3. S112-specific, as well tion of BAD after 4 hr of IL-3 deprivation (Figure 5A).
as S136-specific activities were consistently increased However, BAD phosphorylation was induced approxi-
in the mitochondrial fraction of IL-3-treated cells (Figure mately 12-fold following 15 min of IL-3 exposure. IL-3-
4A). The S112-specific kinase activity was strongly di- inducedphosphorylationofendogenousBADwasinhib-
minishedtonearlybackgroundlevelsfollowingtheaddi- ited by approximately 50% when cells were pretreated
tion of a PKA-specific inhibitory peptide (PKI) to the with the PKA inhibitors Rp-cAMP or H-89, consistent
heavymembranefractionwhiletheS136-specifickinase with the inhibition of S112 but not S136 phosphorylation
activity was unaffected (Figure 4B). Moreover, the addi- (Figures5Aand5B).Infurthersupportofthisconclusion,
tion of 10 mM H-89, an ATP analog that functions as inclusion of a myristoylated PKI peptide that gains ac-
a PKA inhibitor, to the heavy membrane preparation cess into cells also reduced the IL-3-induced phosphor-
reduced the IL-3-induced S112 kinase activity (Figure ylation of endogenous BAD (Figure 5B). These data con-
4C).Collectively,theseresultsimplicatePKAastheprin- firm that PKA phosphorylates endogenous BAD in
response to IL-3. cipal mitochondria-based S112 kinase.Phosphorylation of BAD by Mitochondria-Anchored PKA
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Two distinct regions within the cytoplasmic domain
of the IL-3 receptor bc chain are recognized to result in
separate signal transduction pathways. A membrane
proximal region is essential for JAK-STAT activation,
whileadistal regionisrequiredforactivationof theRAS-
RAF-1-MEK-MAPkinase(MAPK)pathway andthePI3K-
p70 S6 kinase (p70S6K) pathway (Miyajima et al., 1993;
Ihle, 1995). To assess whether these pathways con-
tribute to BAD phosphorylation, a panel of kinase-spe-
cific inhibitors was used. The PI3K inhibitor LY294002
(Vlahosetal.,1994)orWortmannin(datanotshown)also
inhibited the phosphorylation of BAD by approximately
50% (Figure 5A). In addition, the MEK inhibitor PD98059
(Alessi et al., 1995) also partially inhibited (z25%) the
phosphorylation of BAD (Figure 5A). The MEK and PI-
3K inhibitors proved additive in their effect (Figure 5A),
suggesting that both of these pathways, in addition to
the PKA pathway, can contribute to IL-3-induced BAD
phosphorylation. However, the protein tyrosine kinase
inhibitor Genestein and the p70S6K inhibitor Rapamycin
had no effect on the phosphorylation (data not shown).
Furthermore, when inhibitors of PI3K (LY294002), MEK
(PD98059), and PKA (Rp-cAMP) were added simultane-
ously, a consistent, further reduction in phosphorylation
was observed (.75%) (Figure 5A).
To determine whether PKA activity has a biologic role
in survival, we assessed the effects of the PKA inhibitor
H-89 upon FL5.12 BCL-XL/BAD 136A cells, which pos-
sess an intact S112 site. Cells were pretreated with H-89
to inhibit PKA and deprived of IL-3 as a death stimulus.
Approximately 28% more death was observed with the
inhibition of PKA (Figure 5C). A more stringent test of
PKA’ssingularimportancetocellsurvivalaskedwhether
the inhibition of PKA in the continued presence of IL-3
was sufficient to cause death. Cells were deprived of
IL-3 to initiate a death signal, but IL-3 with or without
H-89 was added back at 8 hr before irreversible damage
occurred. Inhibition of PKA was sufficient to kill z20%
of cells even in the presence of IL-3 providing its other
Figure 5. PKA Inhibitors Block IL-3-Induced BAD Phosphorylation survival signaling pathways. The data in Figure 5 sug-
In Vivo gest that PKA as well as PI-3K and MAPK pathways
(A) BAD immunoprecipitates from 32P-labeled FL5.12 BCL-XL/BAD impact BAD phosphorylation and cell survival.
cells were prepared after 4 hr of IL-3 deprivation (2IL-3) or 15 min
following IL-3 readdition (1IL-3). PI-3 kinase inhibitor (LY294002, 10
Anchoring Inhibitor Peptide Inhibits BAD mM), MEK inhibitor (PD98059, 50 mM), and PKA inhibitor (Rp-cAMP,
Ser-112 Phosphorylation In Vivo 100 mM) were added together with 32P-orthophosphate at time 0.
Cellular extracts were immunoprecipitated with an anti-BAD anti- The observation that PKA inhibitors would block the
body (2G11). The experimental time course is shown at the top. mitochondria-based S112 BAD kinase activity (Figure
Percentage values indicate the relative BAD phosphorylation level 4) suggests the involvement of a mitochondria-based
for each treatment when the level of BAD phosphorylation induced AKAP that would localize the PKA holoenzyme to that
by IL-3 is set at 100% as measured by phosphorimage analyzer.
membrane. To examine this, we performed an RII over- Data shown are representative of three independent experiments.
lay experiment. Radiolabeled 32P-RIIa revealed a promi- (B) BAD immunoprecipitates from 32P-labeled FL5.12 BCL-XL/BAD
cells were prepared after 4 hr of IL-3 deprivation (2IL-3) or 15 min nent binding protein in lysates of enriched mitochondria
following IL-3 readdition (1IL-3). The prepared PKA inhibitor, H-89 (Figure 6A). Pretreatment with a peptide (Ht31) of the
(10mM),wasaddedtogetherwith 32P-orthophosphate.Themyristoy- amphipathic a helix representing the site of RII/AKAP
lated PKI peptide (100 mM) was added to the culture medium 30 interaction (Carr et al., 1992) specifically blocked the
min prior to IL-3 readdition. Cellular extracts were immunoprecipi-
interaction of 32P-RIIa with this band as has been shown tated with an anti-BAD antibody (2G11). The experimental time
course is shown in the upper panel. Percentage values indicate the
relative BAD phosphorylation level foreach treatment when the level
of BAD phosphorylation induced by IL-3 is set at 100% as measured
byphosphorimage analyzer.Theeffectiveness ofPKA inhibitionwas to 0.4-fold. Data shown are representative of two independent ex-
confirmed by assessing PKA activity within cellular lysates to the periments.
Kemptide (LRRASLG) substrate. For example, when background (C) FL5.12 BCL-XL/BAD 136A cells in the presence of IL-3 were
PKA activity in IL-3-deprived cells is set as 1.0, the inclusion of 10 pretreated (1) or not (2) with the PKA inhibitor H-89 (10 mM). Follow-
mM H-89 decreased the IL-3-induced PKA activity from 2.7-fold ing IL-3 deprivation, viability wasassessed by trypan blue exclusion.Molecular Cell
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Figure 7. Schematic Representation in which the IL-3-Induced
Phosphorylation of BAD on S112 Is Regulated by Mitochondria-
Anchored cAMP-Dependent Protein Kinase
The observation that the PKA regulatory II subunit (RII),
alongwiththecatalyticsubunit(PKAc),copurifiedduring
the identification of the S112 kinase (Figure 3F) sug-
gested that the anchoring of PKA to the mitochondrial
membranemaybecriticalfortheregulationofBADS112
phosphorylation. To test this thesis, we introduced a
Figure 6. Anchoring Inhibitor Peptide Inhibits BAD Ser-112 Phos- myristoylated Ht31-blocking peptide that serves as a
phorylation In Vivo competitive inhibitor of RII/AKAP interaction in vivo in
(A) The mitochondria-enriched heavy membrane fraction prepared order to globally disrupt anchoring of PKA (Lester et al.,
from FL5.12 BCL-XL/BAD cells in the presence of IL-3 (1) or after 1997). The myristoylated Ht31 peptide inhibited IL-3-
IL-3 withdrawal (2IL-3) were examined using an RII overlay method.
induced phosphorylation of endogenous BAD (z50%), Mitochondrial extracts were size fractionated by SDS-PAGE and
consistent with loss of the S112 portion of phosphoryla- transferred to nitrocellulose. A matched filter was pretreated with
tion (Figure 6C). The control peptide, Ht31P, which con- the Ht31 peptide that disrupts RII/AKAP interactions (1Ht31), and
both filters were hybridized with 32P-labeled RIIa. The arrow indi- tains a proline residue that disrupts the a helix, did not
cates a specific RII-binding protein consistent in size with the 132 alter phosphorylation (Figure 6C). Furthermore, at the
kDa isoform of the mitochondrial AKAP (D-AKAP 1/S-AKAP84). level of the mitochondrial membrane, the IL-3-induced
(B) Western blot of the same mitochondria-enriched heavy mem-
S112-specific kinase activity was selectively reduced brane fraction (as in [A]) was developed with an anti-D-AKAP 1/S-
by treating cells with Ht31 but not Ht31P peptide (Figure AKAP84 Ab (Huang et al., 1997). The prominent immunoreactive
6D). Thus, the displacement of RII-anchored PKA ap- band (arrow) confirms that the comparably sized RII-binding protein
(as in [A]) is the z132 kDa isoform of the mitochondrial AKAP. pears to have essentially eliminated the S112 kinase
(C) BAD immunoprecipitates from 32P-labeled FL5.12 BCL-XL/BAD activity at the mitochondrial membrane.
cells were prepared after 4 hr of IL-3 deprivation (2IL-3) or 15 min
following IL-3 readdition (1IL-3). Myristoylated peptides (200 mM) Discussion were added to the culture medium 30 min prior to IL-3 readdition
as diagrammed in Figure 5B. Cellular extracts were immunoprecipi-
The phosphorylation of BAD following exposure to IL-3 tated with an anti-BAD antibody (2G11). Percentage values indicate
the relative BAD phosphorylation level for each treatment when the provides a link between an extracellular survival factor
level of BAD phosphorylation induced by IL-3 is set at 100% as and altered susceptibility to apoptosis by a posttransla-
measured by phosphorimage analyzer. Data shown are representa- tionalmodificationatthe BCL-2checkpoint.Accumulat-
tive of two independent experiments.
ing evidence suggests a model in which protein kinases (D) The heavy membrane fraction of FL5.12 BCL-XL/BAD cells in-
andphosphatasesarespatiallyandtemporallyactivated duced by IL-3 was used in an in vitro kinase assay to examine
in a cell (Hubbard and Cohen, 1993; Mochly-Rosen, specificity for BAD site-specific substrates. The myristoylated Ht31
and Ht31P peptides were added (as in [C]), except the final concen- 1995; Pawson and Scott, 1997). Here we show that PKA
tration was 100 mM. Data shown are representative of two indepen- isresponsibleforsite-specific,phosphorylatedinactiva-
dent experiments. tionofBADuponS112bothinvitroandinvivo.Compart-
mentalization of the PKA holoenzyme is conferred by
the association of RII subunits with a family of AKAPs. previouslyforRII/AKAPinteractionsinvitro(Rosenmund
et al., 1994). An immunoblot of this same mitochondrial These AKAPs bear subcellular addresses that focus the
PKA holoenzyme in close proximity to preferred sub- fraction was developed with an antibody to D-AKAP
1/S-AKAP84, confirming that this RII-binding protein strates and potentially position the kinase where it can
optimally respond to alterations in cAMP. On the basis represents the z132 kDa isoform of this mitochondrial
AKAP (Figure 6B) (Lin et al., 1995; Huang et al., 1997). of our evidence that the type II PKA holoenzyme is an
IL-3-induced kinase responsible for the S112 phosphor- Only the nonphosphorylated BAD appears to be an
active death agonist found at membrane sites where it ylation of BAD and that a blocking peptide that disrupts
AKAP/RII interactions eliminated the S112-specific BAD canheterodimerizewithBCL-XL/BCL-2(Zhaetal.,1996).Phosphorylation of BAD by Mitochondria-Anchored PKA
419
phosphorylationin vivoatthemitochondria, wepropose to the localization of BCL-2 members to mitochondria
that an anchored pool of PKA performs this function. (deJongetal.,1994;Hockenberyetal.,1990),mitochon-
Consistent with this involvement of PKA, we found a 5- drial dysfunction frequently occurs in apoptosis. This
to 6-fold increment in the level of cAMP and the induced includes alterations of DcM, production of reactive oxy-
phosphorylation of CREB in FL5.12 cells following IL-3 gen species, mitochondrial swelling, and release of cy-
exposure (data not shown). Of note, it is the nonphos- tochrome c (Xiang et al., 1996; Kroemer et al., 1997; Li
phorylated form of BAD that complexes with BCL-XL/ et al., 1997; Vander Heiden et al., 1997). Expression of
BCL-2 at membrane sites, especially mitochondria (Zha each proapoptotic member we have examined, includ-
et al., 1996). This constellation of findings indicates that ing BAX, BAD, and BID, all induce mitochondrial dys-
IL-3 survival signaling triggers the activation of mito- function. The AKAP-mediated tethering of PKA to mito-
chondrial membrane-targeted PKA where active BAD is chondria is an attractive strategy to insure that damage
localized and then inactivated (Figure 7). to this organelle does not occur in the presence of ade-
The inhibition of apoptosis by cAMP has been re- quate survival factor (IL-3). This also raises the possibil-
ported in several systems including the the ability of ity that other mitochondrial substrates beyond BAD may
dibutyryl cAMP to retard the apoptosis of IL-3-deprived exist and influence cell death. AKAPs provide a clear
cells (Berridge et al., 1993). Derivatives of cAMP also example of subcellular signaling specificity that focuses
protected cells from chemotherapy-induced death (von kinase/substrate interactions at the principal sites of
Knethen, 1998). In addition, elevation of cAMP has been action. The distinct AKAP (D-AKAP1/S-AKAP84) that
shown to enhance the responsiveness of retinal gan- targets the outer mitochondrial membrane (Lin et al.,
glion cells to many different trophic factors (Meyer- 1995; Huang et al., 1997) would provide PKA the proper
Franke et al., 1995). The data here provide one target localization to phosphorylate BAD. This does not elimi-
for cAMP effects, the inactivation of the proapoptotic nate the possibility of additional subcellularly focused
molecule BAD. BAD kinase(s).
IL-3 receptor signals are transduced via the associ- Evolving evidence suggests that all proapoptotic
ated bc chain (Miyajima et al., 1993; Ihle, 1995) also BCL-2 members may exist in inactive and active confor-
shared by IL-5 and GM-CSF receptors. Three down- mations (McDonnell et al., 1999). Activation represents
stream pathways are well documented following IL-3 posttranslationalmodificationsinresponsetodeathsig-
receptorstimulationandincludetheJak-Stat,Ras-Raf1- nals that also result in translocation between the cytosol
MEK-MAPK, and PI-3K pathways, which emanate from and mitochondria. The withdrawal of survival factor or
defined regions of the bc chain. While less explored, treatment with staurosporine results in the translocation
elevation of cAMP levels has been reported in IL-3- of monomeric BAXfrom the cytosol tothe mitochondria,
treated 32D cells (Berridge et al., 1993) and GM-CSF- where it is a homodimerized, integral membrane protein
stimulated cells (Coleman et al., 1989). Our initial exami- (Wolter etal., 1997; Gross etal., 1998). TheBH3 domain–
nation of the bc chain indicates that the cAMP response only BID provides another example in which Caspase-8
residesinadistinctregionofthatreceptor.Alternatively, activation by Fas or TNF results in proteolytic cleavage
the IL-3 activation of mitochondria-based PKA could to an active p15 form of BID that targets mitochondria
reflect a more tightly compartmentalized mechanism and releases cytochrome c (Luo et al., 1998; Li et al.,
that enables catalytic activity. 1998; Gross et al., 1999). The phosphorylation of BAD
Inhibitors of PKA, PI-3K, and MEK kinases all di- provides yet another example of how distinct signal
minished BAD phosphorylation in vivo, arguing that a pathways alter death effectors at intracellular sights.
combination of pathways controls BAD activity in IL-3- The differential phosphorylation of BAD indicates the
treatedcells.AKThasbeenimplicatedinthephosphory- complexity of death and survival pathways (Figure 7).
latedinactivation ofBAD inseveral systemsthat overex- This single proapoptotic molecule has two nearly identi-
press both AKT and BAD (Datta et al., 1997; del Peso cal serine phosphorylation sites, both of which bind 14-
et al., 1997; Blume-Jensen et al., 1998). In one of these,
3-3. However, each site has a distinctly different kinase
transiently expressed BAD and AKT were colocalized to
responsible downstream from a single receptor, IL-3R. the perinuclear region providing an explanation (Blume-
This argues that the effects of posttranslational modifi- Jensen et al., 1998). The immunodepletion of AKT per-
cation on the central apoptotic pathway will be sub- formed here did not substantially alter the IL-3-induced
stantial. BAD kinase activity. In that context, AKT is reported to
be principally located at the plasma membrane (Andjel-
Experimental Procedures kovic et al., 1997), while nonphosphorylated BAD re-
sides at the mitochondria and endoplasmic reticulum. Plasmid Construction
This raises an issue as to whether native levels of AKT Standardpolymerasechainreactions(PCRs)wereusedtoconstruct
are solely responsible for the phosphorylation of endog- the GST-BAD fusion plasmids. The BAD cDNAs encompassing
amino acids from 104 to 141 were subcloned between BamHI and enous BAD.
EcoRI sites of pGEX4T-1. The plasmids pSFFV-BADwt, -BAD112A, Another study provided evidence that a MEK-depen-
-BAD136A, and -BAD112A136A (Zha et al., 1996) were used as tem- dent pathway may contribute to the phosphorylation of
plates for amplifying cDNAs with a forward primer of sequence BAD (Scheidand Duronio, 1998).The separationof S136
ATTGGATCCATGGAGACTCGGAGTCGCandareverseprimerofse-
from S112 kinase activity after several chromatographic quence TGCGAATTCTCAGAGATTGGGGGGAGC.
steps provides an opportunity to define the S136-spe-
cific kinase in the IL-3 pathway. Antibodies
An expanding body of data supports a prominent role Anti-BAD antibody (Ab) is a hamster monoclonal Ab (2G11) (Zha et
al., 1996). Anti-AKT Ab is a rabbit polyclonal Ab provided by Dr. for mitochondria in many apoptotic deaths. In additionMolecular Cell
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Philip Tsichlis, Fox Chase Cancer Center. Anti-PKAc and anti-D- (Amicon). Active fractions (0.8 mg of protein) were pooled and buffer
exchanged into buffer C (20 mM Tris [pH 7.5], 1 mM EDTA, 1 mM AKAP1/S-AKAP84 Abs are rabbit polyclonal Abs provided by Dr.
Susan Taylor, UCSD. Anti-PKARII Ab is a rabbit polyclonal Ab pur- DTT, 0.05% Brij-35) using a Sephadex G-25 column. Appropriate
fractions were loaded onto a Mono Q 5/5 column (Pharmacia) equili- chased from Santa Cruz.
brated with buffer C. The column was eluted with a 20 ml linear
gradient of 0–0.5 M NaCl in buffer C. Western Blot Analysis
On the purification described in Figure 3E, after the loading onto The analysis was carried out as described previously (Zha et al.,
a 5 ml HiTrap SP column (46.2 mg of protein), bound proteins were 1996). Anti-AKT Ab was used at 1:1000 dilution, anti-PKAc Ab was
eluted with a 100 ml linear gradient of 0–0.5 M NaCl in buffer B. used at 1:10000, anti-PKARII Ab was used 1:300, anti-D-AKAP 1 Ab
Then ammonium sulfate (1 M) was added to the active fractions was used 1:5000, and the secondary Abs were used at 1:2000.
(11.6 mg of protein) and loaded ontoa1m lphenyl-Sepharose col-
umn, and bound proteins were eluted at the same condition de- RII Overlay
scribed above. The salt-removed, active fractions (2.8 mg of protein) The presence of AKAPs in mitochondrial heavy membrane prepara-
were loadedonto a1 mlReactive Blue4 column(Sigma) equilibrated tions was deleted by a solid phase RII overlay method (Carr et al.,
with buffer B. The column was eluted with a 20 ml linear gradient 1992). Lysates of mitochondria were separated by SDS-PAGE and
of 0–1.0 M NaCl in buffer B. The active fractions (0.432 mg of protein) transferredtonitrocellulose.Filterswithorwithoutpretreatmentwith
were pooled, diluted, and loaded onto a Mono S 5/5 (Pharmacia) 3 mM Ht31 peptide were incubated with 32P-labeled RIIa overnight at
equilibrated with buffer B. The column was eluted with a 20 ml linear room temperature. RII-binding proteins were detected by autoradi-
gradient of 0–0.5 M NaCl in buffer B. ography.
Metabolic Labeling and Immunoprecipitation In Vitro Kinase Assays
FL5.12 BCL-XL/BAD cells were labeled in phosphate-free RPMI1640 The BAD kinase assays were carried out in the presence of 5 mCi
medium with [32P]orthophosphate (1 mCi/107cells) for4 hr. Immuno- of [g-32P]ATP and 50 mM cold ATP in a buffer containing 50 mM
precipitation using an anti-BAD antibody (2G11) was carried out as Tris (pH 7.5), 10 mM MgCl2, 1 mM ditiothreitol (DTT), 10 mM
previously described (Zha et al., 1996). b-glycerophosphate. Each of the GST-BAD fusion proteins was
added at 10 mg. The reaction mixtures were incubated at 308C for
Acknowledgments 20 min and stopped by the addition of SDS-PAGE loading buffer.
Proteins were resolved on an SDS-polyacrylamide gel and were
We are grateful to Dr. Philip Tsichlis for providing the anti-AKT Ab. visualized by autoradiography. The AKT immunocomplex protein
We thank Drs. Andrey Shaw and Helen Piwnica-Worms for their kinase assay was performed as described in Franke et al. (1995).
stimulating discussion and technical comments. We thank Ms. Deb-
orah S. Maher for secretarial assistance. Hisashi Harada is a special
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saline twice, resuspended in a buffer (20 mM Tris [pH 7.5], 25 mM
NaF, 1 mM Na3VO4,1 0m Mb-glycerophosphate, 1 mM DTT, 0.15
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